APLNR and age-related macular degeneration: In summary, this study validates targeting APJ for the treatment of CNV and provides compelling evidence that AQ, a widely used anti-malarial drug, has a strong anti-angiogenic activity in vitro and in vivo in a mouse model of AMD.